Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria  by Treister, Nathaniel S. et al.
From the
Wom
Oral
Denta
statist
stitute
Malig
chuse
Schoo
Financial d
Correspon
DMS
and W
3-028
Received J
 2010 Am
1083-8791
doi:10.101
108Oral Chronic Graft-versus-Host Disease Scoring Using
the NIH Consensus Criteria
Nathaniel S. Treister,1,2 Kristen Stevenson, MS,3 Haesook Kim,3 Sook-Bin Woo,1,2
Robert Soiffer,4,5 Corey Cutler4,5The National Institutes of Health (NIH) Oral chronic Graft-versus-Host Disease (cGVHD) Activity Assess-
ment Instrument is intended to be simple to use and to provide a reproducible objective measure of disease
activity over time. The objective of this study was to assess inter- and intraobserver variability in the com-
ponent and composite scores in patients evaluated with oral cGVHD. Twenty-four clinicians (bone marrow
transplant [BMT] oncologists: BMTE, n 5 16; BMT midlevel providers: BMT MLP; n 5 4; and oral medicine
experts [OME], n 5 4), from 6 major transplant centers scored high-quality intraoral photographs of 12
patients. The same photographs were evaluated 1 week later by the same evaluators. An intraclass correla-
tion coefficient (ICC) was used to calculate intrarater reliability and interrater agreement was analyzed using
aweighted k statistic: 0# k# 0.205 poor, 0.21# k# 0.405 fair, 0.41# k# 0.605moderate, 0.61# k#
0.80 5 good, 0.81 # k # 1.00 5 very good. Data on participant experiences and demographics were also
collected. Mean interrater reliability for each element was poor to moderate (range: 0.15-0.46). Overall
mean kappa scores were highest for ulcers (0.46), followed by erythema (0.23), and lowest for lichenoid
(0.15) andmucoceles (0.14). Kappa scores were higher in OME compared with BMTE and BMTMLP in ulcers
and erythema (eg, 0.85, 0.44, 0.33 for ulcers, respectively), but similar in lichenoid and mucoceles. Overall
intrarater reliability in all groups was very good ($0.90) and highest for ulcers (0.97, 0.85, 0.94). Although
75% of OME were comfortable with their abilities to score the cases, approximately 50% of BMTE and
BMT MLP were uncomfortable. The majority felt that their evaluations were accurate; however, 84% agreed
that formal training is required. Interrater variability of the oral cGVHD instrument is unacceptable for the
purposes of clinical trials. Greater concordance among OME, high intrarater reliability, and participant feed-
back suggests that formal training may significantly decrease variability. Parallel investigations must be com-
pleted using the other organ specific instruments prior to any revision and widespread prospective utilization
of these tools as research endpoints.
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Chronic graft-versus-host disease (cGVHD) is
a serious and potentially life-threatening complication
of allogeneic hematopoietic stem cell transplantation
(allo-HCT) [1-5]. With many hematologic diseases,
malignancies, and bone marrow failure syndromes in-
creasingly being treated with alloHCT, and with con-
tinually improving supportive care measures and
survival rates, cGVHD has become the leading long-
term cause of morbidity and mortality after transplan-
tations [1,6-9]. Treatment of cGVHD is often only
partially effective, and aside from first-line therapy
with high dose corticosteroids, there is no consensus
as to what constitutes standard second-line therapy,
demonstrating the critical need for large-scale, multi-
institutional clinical trials.
One of the main barriers to the conduct of effective
clinical research in cGVHD has been the absence of
standardized criteria for diagnosis, staging, and
Biol Blood Marrow Transplant 16:108-114, 2010 109Oral cGVHD Scoring Using the NIH Consensus Criteriaresponse to therapy [10]. This was recently addressed
by the National Institutes of Health (NIH)-sponsored
Chronic GVHD Consensus Project, from which
a number of consensus documents were published, in-
cluding response criteria guidelines intended to mea-
sure clinical changes over time [11]. Importantly, the
cGVHDActivity Assessment instruments for response
measurement were designed to be easy to use not by
organ-specific specialists (eg, dermatologists and oral
medicine specialists), but rather by transplant physi-
cians, nurses, and physician assistants. None of these
instruments have been prospectively validated, and
the extent to which they may truly be effective in dis-
cerning clinically meaningful changes remains unclear.
The oral cavity is one of the most frequently af-
fected target organs of cGVHD,with prominentmuco-
sal changes including erythema (redness), lichenoid
hyperkeratotic changes (white reticulation and/or pla-
ques), ulceration (yellow-to-white pseudomembranes),
and mucoceles (mucous-filled vesicles) that are well-
visualized during routine clinical examination [12-14].
These featuresmake themouth an excellent representa-
tive site for prospective evaluation of the organ-specific
response criteria. The purpose of this studywas to eval-
uate inter- and intraobserver variability in the Oral
cGVHD Activity Assessment instrument component
and composite scores, and to identify any significant
impediments to its use.METHODS
Twenty clinicians from 6 institutions, including
oncologists (denoted BMTE) and non-MD clinicalFigure 1. NIH Oral cGVHD Activitystaff (nurses, physician assistants, and dental hygien-
ists; denoted BMT MLP) with experience in evaluat-
ing patients with cGVHD reviewed high-quality
intraoral photographs of patients with oral cGVHD.
Photographs were obtained as part of routine clinical
evaluation at the Center for Oral Disease, Brigham
andWomen’s Hospital, Boston, MA. All patients con-
sented to the use of their photographs for teaching and
research purposes. Twelve cases representing a spec-
trum of clinically active and resolved cGVHD, ranging
from mild changes to extensive ulcerations, were
selected for the study and printed in series on photo-
graphic paper. To establish a standard to compare
the evaluators’ responses, 4 oral medicine specialists
(denoted OME) also evaluated the cases via the same
protocol, for a total of 24 raters. This study was ap-
proved by the Dana-Farber/Harvard Cancer Center’s
Office for Human Research Subjects.
Oral cGVHD scoring
The NIH oral cGVHD Activity Assessment is
a 0-15 point objective clinical scoring system that takes
into account (1) severity and extent of erythema, (2)
extent of lichenoid hyperkeratotic changes, (3) extent of
ulcerations, and (4) the number of mucoceles (Figure 1).
Evaluators were instructed to score the cases based
on a global assessment of clinical signs rather than
on any given anatomic site, according to published
guidelines (http://www.asbmt.org) [15]. For example,
to assign a score of ‘‘moderate’’ ulceration, defined as
#20% involvement, 20% of all evaluated sites would
need to demonstrate ulceration, not 20% of a single
anatomic site, such as the right buccal mucosa. Evalu-
ators were instructed to consider any sites that wereAssessment scoring instrument.
Figure 2. Representative series of oral cGVHD photographs.
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or unaffected.
Identical study packets were distributed by mail to
each participant that included detailed instructions,
clinical photographs, an evaluator questionnaire,
scoring forms, and a postage-paid return envelope.
Evaluations of the same 12 cases were completed inde-
pendently 2 times, 1week apart; evaluatorswere explic-
itly instructed not to review their first scores while
completing the second scoring sheet. After the second
evaluation, raters answered a series of questions (using
a 5-point scale) about their ease and comfort with scor-
ing the cases, and entered comments to note any areas
that seemed particularly problematic or unclear. Com-
pleted study materials were returned in the provided
postage paid return envelope (Figure 2).Statistical Analyses
Agreement between raters (interrater agreement)
was analyzed using a weighted Kappa (k) statistic,
which compensates for equivalent ratings because of
chance [16]. The degree of agreement was interpreted
as follows: 0# k# 0.205 poor, 0.21# k# 0.405 fair,
0.41 # k # 0.60 5 moderate, 0.61 # k # 0.80 5 good,
and 0.81 # k # 1.00 5 very good [17]. To investigate
the reliability of the instrument and intrarater agree-
ment, cases were evaluated by raters independently
on 2 occasions, 1 week apart. Intrarater reliability
was estimated using Pearson’s correlation coefficient
and an intraclass correlation coefficient (ICC). Fisher’s
exact test was used to assess differences between cate-
gorical measures.
Consistency between the 3 groups of raters was
evaluated using Pearson’s correlation coefficient and
paired t-tests based on mean total NIH scores calcu-
lated for each case evaluated in each group of raters.
For the comparison of intrarater scores, the mean total
NIH score was calculated for each of the 12 cases for
each group of evaluators. Using each group’s mean to-
tal NIH score per case, pair-wise comparisons between
groups were made using Pearson’s correlation coeffi-
cient as a measure of agreement. Pair-wise differences
in the mean total NIH scores per case were alsocalculated between groups and assessed using a paired
t-test for each evaluation.RESULTS
Forty study packets were distributed; 24 were re-
turned for a 60% response rate. Two responders
(8%) completed only a single evaluation. The demo-
graphic data of the 24 evaluators is summarized in Ta-
ble 1. There was at least 1 evaluator (4%), and no more
than 10 evaluators (42%) from each institution. Most
(75%) considered themselves cGVHD ‘‘experts,’’
which is reflected in the median years of experience
(13, range: 0.5-32). Nearly half (42%) of evaluators
reported previously receiving some type of formal
training in the use of the instrument.
Interrater reliability statistics are summarized in
Table 2. Overall mean kappa scores were highest for
ulcers (0.46), followed by erythema (0.23), and lowest
for lichenoid (0.15) and mucoceles (0.14; all P-values
\.0001). Kappa scores were higher in OME compared
with BMTE and BMTMLP in ulcers (0.85, 0.44, and
0.33, respectively) and erythema (0.40, 0.25, and 0.20,
respectively). lichenoid kappa scores were highest in
BMTMLP and similar in OME and BMTE (0.31,
0.16, and 0.11, respectively). Kappa scores for muco-
celes were universally low. Rating of ulcers by OME
was the only element that demonstrated very good
agreement.
Overall intrarater reliability in all groups was high
(overall ICC 5 0.90, range: 0.88-0.95; Table 3). With
respect to the component scores, there was much
greater consistency in erythema and ulcers (overall
ICC 5 0.86 and 0.92, respectively) compared with li-
chenoid (0.72, range: 0.67-0.82) and mucoceles (0.73,
range: 0.56-0.87).
For the comparison of intrarater scores, the mean
total NIH score was calculated for each of the 12 cases
for each group of evaluators at each evaluation
(Table 4). Overall, there was high agreement in mean
scores among the 3 groups of evaluators (r 5 0.86-
0.99). BMTE (group 2) and BMT MLP (group 3) on
average, consistently had a higher mean total score
Table 1. Evaluator Demographics
N (%)
Number of evaluators 24
Age (years), median (range) 44 (32, 59)*
Experience (years), median (range) 13 (0.5, 32)
Sex
Female 8 (33)
Male 16 (67)
Institution
University of North Carolina 3 (13)
University of Minnesota 1 (4)
Dana-Farber Cancer Institute/BWH 10 (42)
Fred Hutchinson Cancer Research Center 7 (29)
Northwestern University/Children’s Memorial Hospital 2 (8)
Stanford University 1 (4)
Clinician type
Medical staff (‘‘BMT Expert’’) 16 (67)
Dental hygienist (‘‘BMT MLP’’) 1 (4)
Oral medicine staff (‘‘OM Expert’’) 4 (17)
Nursing staff (‘‘BMT MLP’’) 3 (12)
Primary institutional responsibility
Clinical 17 (71)
Research 4 (17)
Clinical and research 2 (8)
No response 1 (4)
Does rater consider him/herself a cGVHD expert?
Yes 18 (75)
No 6 (25)
Has rater received formal training
Yes 10 (42)
No 13 (54)
Unknown 1 (4)
Oral medicine specialist is part of clinical team
Yes 16 (67)
No 8 (33)
OM indicates oral medicine; BMT MLP, bone marrow transplantation
midlevel provider; cGVHD, chronic graft-versus host disease.
*Three evaluators did not report age.
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confidence interval] 5 20.81 [ 2 1.57, 20.05], 21.30
[ 2 2.07, 20.51], respectively, at the first evaluation;
21.09 [2 1.63,20.54],21.77 [2 2.50,21.05], respec-
tively, at the second evaluation), even though the mag-
nitude of the difference was relatively small (Table 4).
Responses to the postevaluation questionnaire are
summarized in Table 5. The most frequently reported
areas of difficulty were (1) assessment of mucocelesTable 2. Summary of Interrater Reliability
Type
Overall Mean
Kappa E1 (SE), E2 (SE)
OME Mean
Kappa E1 (SE), E2 (
No. of raters 23* 4
Type
Erythema 0.23 (0.02), 0.23 (0.02) 0.45 (0.13), 0.35 (0.
Lichenoid 0.15 (0.02), 0.14 (0.02) 0.15 (0.01), 0.16 (0.
Mucoceles 0.17 (0.02), 0.12 (0.01) 0.08 (0.08), 0.02 (0.
Ulcers 0.45 (0.03), 0.47 (0.03) 0.80 (0.12), 0.89 (0.
Total* 0.29 (0.02), 0.28 (0.02) 0.56 (0.12), 0.56 (0.
E1 indicates evaluation #1; E2, evaluation #2; SE, standard error; 0# k# 0.20
0.80 5 good, and 0.81 # k # 1.00 5 very good; OME, oral medicine expert; BM
transplantation midlevel provider.
*Rater 21 filled out (one initial, one follow-up); rater 21 filled out only the first e
23 total raters at each evaluation, although 24 total participated.
*Total score was categorized as 0-5, 6-10, and 11-16.(54%), (2) artifact from the camera flash (29%), (3)
determining the percentage of involvement (17%).
Although 75% of OME were comfortable with their
abilities to score the cases, approximately 50% of
BMTE and BMTMLP were uncomfortable. This is
also reflected in the time required to complete the eval-
uations. The majority (58%) felt that their evaluations
were accurate, with only 3 evaluators (13%, all BMTE)
answering inaccurate. There was overwhelming con-
sensus (84%) that formal training is required for
accurate and effective use of the instrument.DISCUSSION
This is the first study to evaluate inter- and intra-
observer variability in the recently introduced NIH
consensus criteria for scoring oral cGVHD. As the
oral cavity is one of the most frequently affected sites
[13,14], and easily examined clinically [18,19], we felt
that this was an ideal target organ to examine vari-
ability parameters. Although the intent of this instru-
ment is to provide an objective, reproducible score
that accurately reflects the extent and severity of clin-
ical disease, which generally correlates with symp-
toms [15,19], its functionality has yet to be
demonstrated. Importantly, it was not our intent to
evaluate the overall utility or validity of the scoring
system, with respect to its ability to accurately mea-
sure disease severity and changes over time. In fact,
to date, few studies using the NIH instruments have
been published [11,20-22]. Elad et al. [23] recently re-
ported only moderate correlation between NIH total
scores and pain scores (r 5 .45, P\ .001). Although
they found strong correlations between total scores
and erythema/ulceration scores, they also found that
cases rated as ‘‘severe’’ based on erythema/ulceration
versus lichenoid were significantly different, suggest-
ing that such findings should not be classified at the
same intensity level.
Overall interrater reliability ranged from poor to
fair, with assessment of ulcers receiving the highestSE)
BMTE Mean
Kappa E1 (SE), E2 (SE)
BMT MLP Mean
Kappa E1 (SE), E2 (SE)
15 4
12) 0.26 (0.03), 0.24 (0.03) 0.14 (0.10), 0.26 (0.10)
14) 0.11 (0.03), 0.10 (0.03) 0.34 (0.09), 0.28 (0.08)
08) 0.16 (0.02), 0.13 (0.02) 0.11 (0.08), 0.02 (0.09)
12) 0.42 (0.04), 0.45 (0.04) 0.33 (0.10), 0.32 (0.10)
12) 0.29 (0.02). 0.28 (0.02) 0.14 (0.11), 0.14 (0.11)
5 poor, 0.21# k# 0.405 fair, 0.41# k# 0.605moderate, 0.61# k#
TE, bone marrow transplantation oncologist; BMT MLP, bone marrow
valuation, while rater 22 filled out only the second evaluation, resulting in
Table 3. Intrarater Reliability
Overall r, Mean ICC (Range) OME r, Mean ICC (Range) BMTE r, Mean ICC (Range) BMT MLP r, Mean ICC (Range)
No. of raters 22* 4 14 4
Type
Erythema 0.76, 0.86 (0.66, 1.00) 0.81, 0.91 (0.83, 1.00) 0.72, 0.83 (0.66, 0.93) 0.88, 0.94 (0.92, 1.00)
Lichenoid 0.67, 0.72 (0.31, 1.00) 0.65, 0.67 (0.39, 0.87) 0.65, 0.70 (0.31, 0.88) 0.72, 0.82 (0.67, 1.00)
Mucoceles 0.71, 0.73 (20.33, 0.96) 0.80, 0.87 (0.77, 0.94) 0.71, 0.74 (0.18, 0.96) 0.56, 0.56 (20.33, 0.94)
Ulcers 0.85, 0.92 (0.68, 1.00) 0.96, 0.98 (0.91, 1.00) 0.81, 0.89 (0.68, 1.00) 0.92, 0.96 (0.84, 1.00)
Total 0.83, 0.90 (0.61, 0.99) 0.90, 0.95 (0.93, 0.99) 0.79, 0.88 (0.61, 0.95) 0.88, 0.94 (0.91, 0.96)
r indicates Pearson’s correlation coefficient; ICC, intraclass correlation coefficient; OME, oral medicine expert; BMTE, bone marrow transplantation
oncologist; BMT MLP, bone marrow transplantation midlevel provider.
*Two BMTE raters only completed a single evaluation resulting in 22 rather than 24 evaluators.
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demonstrated the highest scores in the range of very
good; however, no other clinical features approached
this level, regardless of the group evaluating. Ulcers
can be easily differentiated from nonulcerated mucosa,
the spatial assessment parameters (none, \20%,
$20%) are simple to interpret, and there are only 3 op-
tions compared with 4 in the other features. This is in
contrast with erythema, for example, where gradations
may be more difficult to discern, and the spatial assess-
ments are far more complex. Similar levels of modest
concordance (ICC across sequential trials ranged
from 0.57 to 0.70) between clinicians and experts using
the NIH response criteria oral evaluation measures
have been demonstrated by other investigators [24].
Of note, these investigators also observed that 83%
of NIH response criteria clinician-assessed oral total
scores (15 point instrument score range) were within
2 points of oral medicine experts’ reference values.
Intrarater variability, in contrast, was far lower,
with most overall mean kappa scores in the very good
range. This is reflected in the finding that the majority
(58%) felt comfortable with their ability to accurately
score the cases. This suggests that with adequate train-
ing to ensure consistent use of the oral instrument (and
by extension the other organ-specific instruments), ac-
curate data can be collected in the context of cGVHD
clinical trials. As the 60% response rate included
representation from multiple centers, it is unclear to
what extent theremay have been significant differencesTable 4. Comparison of Total Scores between Groups
Correlation (r),
(Mean Difference,* [95% CI]) Evaluation OME B
OME E1 — 0.86 (20.81,
E2 — 0.93 (21.09,
BMTE E1 — —
E2 — —
BMTMLP E1 — —
E2 — —
OME indicates oral medicine expert; BMTE, bone marrow transplantation on
confidence interval.
*Mean differences are calculated as follows: Group 1-Group 2; Group 1-Grou
†Denotes the 95% confidence interval excludes zero; P < 0.05 for the pairedbetween responders and nonresponders, which may
have influenced study outcomes. The higher concor-
dance rate among oral medicine specialists suggests
that organ-specific experts should be involved in clin-
ical trials at the level of training and calibration, and/or
central data review.
The use of photographs allowed the participation
of multiple clinicians at various centers throughout
the United States. Although a similar approach of us-
ing clinical photographs to assess inter- and intraob-
server variability in scoring has been previously
employed, it is unclear how well interpretation of pho-
tographs reflects actual clinical observation, with
respect to the ability to identify and discriminate spe-
cific findings [25,26]. Of note,.50% of evaluators re-
ported difficulty assessing mucoceles, reflected in the
very poor interrater variability for this feature (Table
2). This may have been explained by either the pres-
ence of flash artifact from the camera, or difficulty in
discerning a raised, often colorless lesion in 2 dimen-
sions, rather than evaluators’ inability to clinically
identify these lesions [27-29]. In fact, overall intrarater
variability for mucoceles was good, demonstrating con-
sistency regardless of any reported difficulties. An-
other reported complication was the ability to
estimate percentages of involved mucosa, a critical
component of evaluating lichenoid, erythematous,
and ulcerative changes, suggesting that more specific
guidelines might be necessary for optimal utilization
of this instrument. Similar concerns with the abilityMTE BMTMLP Mean (SE)
[21.57, 20.05]†) 0.87 (21.30, [22.07, 20.51]†) 6.00 (0.60)
[21.63,20.54]†) 0.87 (21.77, [22.50, 21.05]†) 6.06 (0.62)
0.94 (20.48, [21.01, 0.05]) 6.81 (0.71)
0.99 (20.68, [20.91, 20.46]†) 7.15 (0.69)
— 7.29 (0.74)
— 7.83 (0.71)
cologist; BMTMLP, bone marrow transplantation midlevel provider; CI,
p 3; Group 2-Group 3.
t-test.
Table 5. Evaluators’ Experiences Using the NIH Oral cGVHD Response Criteria Scoring System
All OME BMTE BMTMLP P-value
N 24 4 16 4
How long did this set of evaluations take to complete?
#30minutes 9 (37) 2 (50) 6 (38) 1 (25) .87
>30minutes 12 (50) 2 (50) 7 (44) 3 (75)
No response 3 (13) 0 (0) 3 (19) 0 (0)
What part(s), if any, did you have trouble with?*
Determining % involvement 4 (17) 2 2 0
Spatial orientation 1 (4) 0 1 0
Assessment of erythema 2 (8) 1 1 0
Assessment of mucoceles 13 (54) 2 9 2
Flash reflection 7 (29) 1 5 1
Representation of ulcers 3 (13) 1 1 1
Color representation/variation 2 (8) 1 0 1
How comfortable were you with your ability to score these cases?
Uncomfortable 9 (38) 0 (0) 7 (44) 2 (50) .44
Neither/no response 3 (12) 1 (25) 2 (13) 0 (0)
Comfortable 12 (50) 3 (75) 7 (44) 2 (50)
How would you rate the accuracy of your evaluations?
Inaccurate 3 (13) 0 (0) 3 (19) 0 (0) >.99
Neither/No response 7 (29) 1 (25) 5 (31) 1 (25)
Accurate 14 (58) 3 (75) 8 (50) 3 (75)
Do you feel that formal training is required to accurately and effectively use this scoring system?
Disagree 2 (8) 0 (0) 2 (13) 0 (0) .83
Neither/no response 2 (8) 0 (0) 1 (6) 1 (25)
Agree 20 (84) 4 (100) 13 (81) 3 (75)
NIH indicatesNational Institutes of Health; cGVHD, chronic graft-versus-host disease; OME, oral medicine expert; BMTE, bonemarrow transplantation
oncologist; BMTMLP, bone marrow transplantation midlevel provider.
*Evaluators may have included more than one part that was considered problematic.
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with respect to the skin cGVHD response criteria
(ie, deep sclerosis) have been recently reported by
others [22].
The instructions that were provided for the evalu-
ators were comprehensive yet succinct, and did not in-
clude a specific training module or sample cases. This
was intentional, so that there would be no potential
bias if training compliance was variable. Of note, par-
ticipants responded overwhelmingly (84%) that for-
mal training should be required prior to application
in the context of a clinical trial. Although we only eval-
uated the oral instrument, similar considerations for
skin cGVHD evaluations would be expected given
the instrument’s various features that must be assessed
(erythema, movable, and nonmovable sclerosis, ulcer-
ation, percentage of body surface area involved)
[15,22]. Development of a coordinated training re-
source should be considered prior to commencing
large-scale cGVHD clinical trials utilizing the new cri-
teria, regardless of the level of experience and area of
clinical expertise of those performing assessments. Of
note, our data demonstrated that as long as clinicians
are experienced in managing patients with cGVHD,
their specific training or credentials have minimal, if
any, impact on the ability to perform effective evalua-
tions (Table 4).
Establishment of clinically meaningful and simple
to use research instruments was a key outcome of the
NIH conference [10,15]. Although the use of these in-
struments is certain to advance our understanding ofcGVHD, studies such as the present are critically
important in defining their strengths and weaknesses
so that they can be further refined andmodified for op-
timal utilization. Equally as important, studies are
needed to assess the instruments validity and clinical
significance in the context of interventional clinical
trials. Such initiatives can only be achieved by multiin-
stitutional collaborations, with the common goal of
minimizing the morbidity of cGVHD.AKNOWLEDGMENTS
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